HOME >> BIOLOGY >> NEWS
Creation of gene targeting earns Smithies March of Dimes honor

CHAPEL HILL--For developing an indispensable tool for genetic disease research, two scientists have been named co-recipients of this year's March of Dimes Prize in Developmental Biology, to be awarded Monday (May 16) in Washington, D.C.

Drs. Oliver Smithies, Excellence Professor of pathology and laboratory medicine at the University of North Carolina at Chapel Hill School of Medicine, and Mario R. Capecchi, Distinguished Professor of human genetics at the University of Utah, are being honored for developing gene targeting.

Their technique gives scientists around the world the ability to alter particular genes in cultured cells and transfer those targeted genes to laboratory mice. Gene targeting thus allows them to design and produce "knockout" lab mice to study how the disabled gene works.

The same technology also makes it possible to change the function of a gene "knock in" -- or restore the function of a disabled gene. Because humans share the vast majority of their genes with mice, gene-targeted mice are used to reproduce diseases that occur in humans.

The March of Dimes Prize is a cash award of $250,000 and a silver medal in the design of the Roosevelt dime, in honor of President Franklin Delano Roosevelt, who founded the March of Dimes.

"Before gene targeting, researchers could not pinpoint how a specific gene worked, which was very frustrating," said Dr. Jennifer L. Howse, president of the March of Dimes. "Dr. Capecchi and Dr. Smithies, working independently, made a technological breakthrough that completely revolutionized biomedical research and our ability to study human disease and development. We're reaping the benefits every day with advances in genetic medicine."

Gene targeting is now practiced routinely by thousands of scientists all over the world, enabling them to address the most complex and critical biological problems, including the causes and treatment of birth defects and many other disorders, such
'"/>

Contact: David Williamson
919-962-8596
University of North Carolina at Chapel Hill
11-May-2005


Page: 1 2

Related biology news :

1. Creation of an international industrial chair in life cycle assessment
2. Creation of an international research network
3. Creation of antibiotic in test tube holds promise for better antibiotics
4. Creationism is not science making the case for Darwin at UCL
5. Bulls-eye -- Programs targeting math, science teacher shortage may get boost
6. AACR Annual Meeting showcases significant developments in understanding and targeting cancers
7. Researchers find stem-cell therapy effective in targeting metastatic cancer
8. By analyzing and targeting specific germs, hospital hopes to improve pneumonia treatment
9. Pain killer fights breast cancer by targeting key enzyme
10. Oncologists could gain therapeutic advantage by targeting telomere protein
11. Understanding IGF-1: Jefferson researcher sees drug potential in targeting enzyme

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Creation gene targeting earns Smithies March Dimes honor

(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
(Date:5/27/2015)... May 27, 2015 RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... it has commenced a public offering of shares ... of its common stock and overallotment purchase rights ... shares of common stock, warrants and overallotment purchase ...
(Date:5/27/2015)... , May 26, 2015 Research and ... the "Global Breast Cancer Monoclonal Antibodies Market ... Globally, Roche seems to dominate the breast ... Its block buster molecule, Herceptin has been able ... was found that breast cancer cells become recalcitrant ...
(Date:5/27/2015)... 27, 2015 Expanding in a big ... Avalon Biomed Inc. recently inked a deal ... Dental Co. Ltd. , the largest endodontic distributor in ... international market for Avalon Biomed, which manufactures Grey MTA ... silicate-based dental cements that have won renown from dentists ...
(Date:5/27/2015)... , May 27, 2015  Tikcro Technologies Ltd. (OTCQB: ... March 31, 2015. Aviv Boim ... continued pre-clinical work to generate functional specific antibodies, targeting ... stage, we are encouraged by the development progress. We ... new antibodies which modulate immune checkpoints gain clinical acceptance ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3
Cached News: